Pre-made Alsevalimab benchmark antibody ( Whole mAb, anti-VTCN1 therapeutic antibody, Anti-B7-H4/B7H4/B7S1/B7X/B7h.5/PRO1291/VCTN1 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-019

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-019 Category Tag

Product Details

Pre-Made Alsevalimab biosimilar, Whole mAb, Anti-VTCN1 Antibody: Anti-B7-H4/B7H4/B7S1/B7X/B7h.5/PRO1291/VCTN1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Products Name (INN Index)

Pre-Made Alsevalimab biosimilar, Whole mAb, Anti-VTCN1 Antibody: Anti-B7-H4/B7H4/B7S1/B7X/B7h.5/PRO1291/VCTN1 therapeutic antibody

INN Name

Alsevalimab

Target

VTCN1

Format

Whole mAb

Derivation

NA

Species Reactivity

Human

CH1 Isotype

IgG1

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Phase-I

Est. Status

Active

100% SI Structure

None

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

2019

Companies

Five Prime Therapeutics

Conditions Approved

NA

Conditions Active

Solid tumours

Conditions Discontinued

NA

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

VTCN1

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide